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Novel role for the CRTC2 in lipid homeostasis
Insulin resistance, a state of reduced
responsiveness to insulin, is frequently
associated with obesity, which subse-
quently leads to type 2 diabetes. Although
major advances have been made in unrav-
eling the underlying mechanisms that
cause insulin resistance, many of the path-
ways and regulators that link insulin to its
downstream metabolic effects are not
completely understood.
Studies in rodent models showed a
peculiar feature of hepatic insulin resis-
tance, namely its selectivity. Insulin exerts
two predominant actions in the liver: (i)
it suppresses glucose production (gluco-
neogenesis); and (ii) it activates the syn-
thesis of fatty acids and triglycerides
(lipogenesis). However, in the insulin-
resistance state, insulin fails to suppress
gluconeogenesis, and lipogenesis is para-
doxically overactivated. As suggested by
Brown and Goldstein1, the signaling
pathways utilized by insulin to stimulate
sterol regulatory element-binding protein
(SREBP)-1c could remain intact in obe-
sity and type 2 diabetes, even as the
pathways that regulate glucose metabo-
lism become resistant. These dual actions
contribute to the lethal combination of
hyperglycemia and hypertriglyceridemia
that characterizes the diabetic state.
Increased lipogenesis observed in the
insulin-resistant state is partially because
of dysregulation of the master transcrip-
tional regulator of lipogenesis, the
SREBP-1c. The SREBP family consists of
three isoforms: SREBP-1a, SREBP-1c and
SREBP-22. SREBP-1c is an isoform that
controls the biosynthesis of fatty acids
and triglycerides by increasing transcrip-
tion of genes encoding acetyl-CoA car-
boxylase, fatty acid synthase, elongation
of very long chain fatty acids family
member 6, stearoyl-CoA desaturase and
others. Insulin activates SREBP-1c
through at least two mechanisms: (i) it
increases SREBP-1c transcription; and (ii)
it increases the proteolytic cleavage of
SREBP-1c from an inactive endoplasmic
reticulum membrane-bound precursor to
release their N-terminal domain capable
of translocating to the nucleus to activate
transcription (Figure 1).
In hepatocytes, insulin signaling
through phosphatidylinositol 3-kinase
and Akt results in the activation of
SREBP-1c expression and accumulation
of nuclear SREBP-1c protein. The
mammalian target of rapamycin complex
1 (mTORC1) is the major phosphatidyli-
nositol 3-kinase/Akt downstream effector,
because insulin-stimulated SREBP activa-
tion and lipogenesis are both blocked by
the mTORC1 inhibitor rapamycin. In
addition, lipin-1, a phosphatidic acid
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Figure 1 | The mammalian target of rapamycin (mTOR) pathways involved in the regulation of
sterol regulatory element-binding protein (SREBP)-1. There are multiple signals that regulate
expression, endoplasmic reticulum (ER)-to-Golgi transport and the proteolytic cleavage of SREBP-
1c. The mTOR pathways involved in the regulation of SREBP-1. During feeding, Sec31A, a subunit
of the coat protein complex II (COPII) complex, dissociates from cyclic adenosine
monophosphate response element-binding protein (CREB) regulated transcription coactivators
(CRTC)2, which becomes phosphorylated at Ser136 by mTOR, and interacts instead with Sec23A,
thus promoting COPII-dependent transport and processing of SREBP-1 in the Golgi. In obesity,
enhanced phosphorylation of CRTC2 by mTOR partially contributes to increase SREBP-1
activation and hepatic lipogenesis. The mTOR pathways are also able to increase SREBP-1c
messenger ribonucleic acid (mRNA), and activate the processing of SREBP-1c and maximal
lipogenic gene expression. C, sterol regulatory element-binding protein C-terminal fragment; N,
sterol regulatory element-binding protein N-terminal fragment; SCAP, sterol regulatory element-
binding protein cleavage-activating protein.
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COMMENTARY
phosphatase and transcriptional coactiva-
tor, is a direct substrate of mTORC1 and
regulator of nuclear SREBP activity.
Lipin-1 phosphorylation by mTORC1
blocks lipin’s nuclear localization and
activates SREBP-1c activity. In the insu-
lin-resistant state, insulin might continue
to activate mTORC1 while losing its
ability to inhibit forkhead box O1.
The cyclic adenosine monophosphate
(cAMP) response element-binding protein
(CREB)-regulated transcription coactiva-
tors (CRTCs) physically interact with
CREB through its N-terminal portion, and
coactivate the transcriptional activity of
CREB through its C-terminally located
transactivation domain. cAMP-dependent
activation of this transcriptional machin-
ery promotes hepatic gluconeogenic pro-
grams by upregulation of key enzyme
genes, such as phosphoenolpyruvate
carboxykinase and glucose-6-phosphatase
catalytic subunit3,4. Although the function
of CRTCs in the liver has been extensively
studied in the context of gluconeogenesis,
Han et al.5 recently showed that cytosolic
CRTC2, as a critical mediator of mTOR,
modulates coat protein complex II
(COPII) activity, which subsequently leads
to SREBP-1 processing and enhancement
of de novo lipogenesis.
These authors measured hepatic lipid
levels in Crtc2+/+ and Crtc2-/- mice. They
found that Crtc2-/- mice showed
increased hepatic triglyceride levels, but
not cholesterol, when compared with
Crtc2+/+ mice fed with both regular chow
and a high-fat diet. Transcript analysis
showed speciﬁc upregulation of SREBP1-
target genes involved in triglyceride syn-
thesis in the livers of Crtc2-/- mice. In
Crtc2-/- mice fed with both chow and a
high-fat diet, the active, nuclear SREBP-1
was signiﬁcantly increased while the pre-
cursor, full-length SREBP-1 was slightly
decreased, although total Srebp-1c mRNA
levels remained unchanged. These results
suggest that CRTC2 mediates SREBP-1
activity at the post-transcriptional level.
In addition, the abnormal nuclear
SREBP-1 accumulation and the enhanced
lipogenic gene expression in Crtc2-/-
mice were normalized to the level found
in fed Crtc2+/+ mice by adenovirus-
mediated CRTC2 overexpression or
knockdown of Srebp-1. Taken together,
these results show that CRTC2 modu-
lates triglyceride synthesis through regu-
lation of SREBP-1 maturation.
In the liver, cAMP signaling activates
CRTC2 activity through Ser171 dephos-
phorylation resulting in its nuclear local-
ization and increased association with
CREB on the promoters of gluco-
neogenic genes. Han et al.5 examined the
effects of the cellular localization of
CRTC2 on SREBP1 maturation using
two CRTC2 mutants: (i) DTAD (amino
acids 1–630), which lacks the transactiva-
tion domain, but still shuttles between
the cytoplasm and nucleus; and (ii)
DTAD/AA, which is conﬁned to the
nucleus because of serine-to-alanine
mutations at positions 171 and 275. Sim-
ilar to wild-type CRTC2, the DTAD
mutant also blocks SREBP-1 maturation
in Crtc2-/- mice, whereas DTAD/AA
mutant was not able to suppress the pro-
cessing of SREBP-1, suggesting that
SREBP-1 processing depends on cytosolic
but not nuclear CRTC2.
Using mass spectrometry and co-
immunoprecipitation analysis, they found
that CRTC2 binds to proteins involved
in SREBP-1 transport regulation. Insulin
regulates SREBP activity through stimula-
tion of endoplasmic reticulum-to-Golgi
SREBP-1c transport by promoting its
phosphorylation and association with
COPII vesicles. Indeed, CRTC2 binds to
Sec31A, a subunit of the COPII complex,
and negatively regulates SREBP-1 pro-
cessing by competing with Sec23A for
binding to Sec31A.
Finally, Han et al.5 found that the
CRTC2–Sec31 interactions modulate
hormonal and nutritional activation of
SREBP-1. Indeed, both insulin and amino
acid stimulation attenuated the CRTC2–
Sec31A interaction with concomitant
enhancement of the Sec23A–Sec31A asso-
ciation. The regulatory effects of CRTC2
on the Sec23–Sec31A interaction were
inhibited in the presence of torin1, an
inhibitor of mTOR, which controls lipid
metabolism and SREBP-1 activation. The
conserved serine site at position 136 of
CRTC2, which occurs in the context of a
classic mTOR substrate motif (S/T-P), was
phosphorylated without and dephospho-
rylated with rapamycin treatment. In
addition, a co-immunoprecipitation assay
and in vitro kinase assay showed that
mTOR interacts with CRTC2, and mTOR
directly phosphorylates CRTC2 at Ser136.
Both insulin and amino acids stimulate
CRTC2 Ser136 phosphorylation in an
mTOR-dependent manner, suggesting
that CRTC2 is a bona ﬁde substrate of
mTOR. Taken together, these results show
that mTOR modulates COPII-dependent
SREBP1 processing through Ser136 phos-
phorylation of CRTC2 (Figure 1).
The elegant study by Han et al.5
greatly advances our understanding of
the speciﬁc signaling pathways by which
insulin stimulates lipogenesis, and pro-
vides new insight into how SREBP-1
activity is enhanced in obesity and type 2
diabetes. This study thus identiﬁes
mTOR-CRTC-SREBP-1 signaling as a
potential therapeutic target for ameliorat-
ing hyperglycemia, hypertriglyceridemia
and hepatic steatosis in type 2 diabetes.
Further unveiling of the molecular mech-
anism(s) that regulate this signaling axis
in obesity and diabetes will hopefully
result in effective ways to overcome insu-
lin resistance and provide a basis for
beneﬁcial treatment of type 2 diabetes.
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